Acquisition of a FLIPR 3 system (384-well Type B head)

购置 FLIPR 3 系统（384 孔 B 型头）

• 批准号: 6731036
• 负责人: HEIDI E HAMM
• 金额: $ 45.37万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6731036
• 关键词: biological products; biomedical equipment purchase; biotherapeutic agent; cells; chemicals; drug discovery /isolation; fluorimetry; high throughput technology; imaging /visualization /scanning; ligands; receptor; small molecule

DESCRIPTION (provided by applicant): Funds are requested for the purchase of a Molecular Devices' FLIPR 3 System (FLIPR 3) equipped with a 384 - Type B head. The FLIPR 3 is a fluorometric imaging, high throughput plate reader that can be used to detect, in real time, fluorescence signals emanating from cell-based assays. Therefore, it can be used to rapidly study, detect and characterize biologically significant cell receptors, ligands or small molecule chemical compounds that may be therapeutically beneficial. At present, this type of instrument is currently unavailable to Vanderbilt University Investigators. The primary user group for the FLIPR 3 is 7 NIH-funded investigators from the Pharmacology, Microbiology and Immunology, Molecular Physiology and Biophysics, Chemistry and Biochemistry Departments at Vanderbilt University. The FLIPR 3 will be used to study and detect molecules associated with thrombin and protease-activated receptors, targeting and trafficking of G protein-coupled receptors, glyceryl-prostaglandin receptors, neurotransmitter transporters and metabotropic receptors related to Parkinson's disease inter alia. The goals of these studies are to identify target molecules for drug development or small chemical inhibitors/agonists that can be used therapeutically for the treatment of disease. The instrument also will be used by the Molecular Recognition and Screening Facility (MRSF)to rapidly detect and characterize antigen specific or biologically active recombinant ScFv antibodies stemming from phage antibody libraries. The instrument will be located in the MRSF. The MRSF was established in 1996 and operates under the auspices of the Vanderbilt Institute of Chemical Biology (VICB). The MRSF is a core facility that is open to Vanderbilt investigators and serves several NIH-funded centers on campus. Additionally, the MRSF services the needs of scientists from local universities such as Meharry Medical College. The MRSF is directed by Dr. Ray Memaugh, who has over twenty years experience in assay and antibody development. Dr. Mernaugh will oversee the operation, maintenance, and scheduling of the FLIPR 3 in consultation with the Executive Committee of the VICB. The Principal Investigator of the present application, Dr. Heidi Hamm is a member of the VICB Executive Committee, which provides continuity between the user group and an independent oversight committee. Dr. Larry Mamett, one of the major users of the FLIPR 3 is Director of the VICB and has pledged long-term support for the maintenance of the instrument from Institute funds.

描述（由申请人提供）：申请资金用于购买配备384 - B型头的Molecular Devices公司的FLIPR 3系统（FLIPR 3）。FLIPR 3是一种荧光成像，高通量板读取器，可用于检测，在实时，荧光信号从基于细胞的分析发出。因此，它可用于快速研究、检测和表征生物学上重要的细胞受体、配体或可能具有治疗益处的小分子化合物。目前，范德比尔特大学的研究人员还无法获得这种类型的仪器。